425 related articles for article (PubMed ID: 7670118)
1. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
2. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
3. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111
[TBL] [Abstract][Full Text] [Related]
4. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.
Faber LM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Exp Med; 1992 Nov; 176(5):1283-9. PubMed ID: 1402674
[TBL] [Abstract][Full Text] [Related]
5. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.
Falkenburg JH; Faber LM; van den Elshout M; van Luxemburg-Heijs SA; Hooftman-den Otter A; Smit WM; Voogt PJ; Willemze R
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):305-9. PubMed ID: 8280712
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R
J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279
[TBL] [Abstract][Full Text] [Related]
7. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens.
Niederwieser D; Grassegger A; Auböck J; Herold M; Nachbaur D; Rosenmayr A; Gächter A; Nussbaumer W; Gaggl S; Ritter M
Blood; 1993 Apr; 81(8):2200-8. PubMed ID: 8471780
[TBL] [Abstract][Full Text] [Related]
8. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
9. Multiple minor histocompatibility antigen disparities between a recipient and four HLA-identical potential sibling donors for bone marrow transplantation.
Marijt EA; Veenhof WF; Goulmy E; Kluck PM; Brand A; Willemze R; van Rood JJ; Falkenburg JH
Hum Immunol; 1993 Aug; 37(4):221-8. PubMed ID: 8300407
[TBL] [Abstract][Full Text] [Related]
10. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.
Vogt MH; van den Muijsenberg JW; Goulmy E; Spierings E; Kluck P; Kester MG; van Soest RA; Drijfhout JW; Willemze R; Falkenburg JH
Blood; 2002 Apr; 99(8):3027-32. PubMed ID: 11929796
[TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact.
Marijt WA; Veenhof WF; Goulmy E; Willemze R; van Rood JJ; Falkenburg JH
Blood; 1993 Dec; 82(12):3778-85. PubMed ID: 8260714
[TBL] [Abstract][Full Text] [Related]
12. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
[TBL] [Abstract][Full Text] [Related]
13. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
Warren EH; Greenberg PD; Riddell SR
Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
[TBL] [Abstract][Full Text] [Related]
15. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
17. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
18. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
19. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
van Lochem E; de Gast B; Goulmy E
Bone Marrow Transplant; 1992 Aug; 10(2):181-3. PubMed ID: 1525608
[TBL] [Abstract][Full Text] [Related]
20. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
